- Home
- CGEN vs OCCI Comparison
CGEN vs OCCI Comparison
Compare CGEN & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- OCCI
- Stock Information
- Founded
- CGEN 1993
- OCCI N/A
- Country
- CGEN Israel
- OCCI United States
- Employees
- CGEN N/A
- OCCI N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- OCCI Trusts Except Educational Religious and Charitable
- Sector
- CGEN Health Care
- OCCI Finance
- Exchange
- CGEN Nasdaq
- OCCI Nasdaq
- Market Cap
- CGEN 167.4M
- OCCI 160.5M
- IPO Year
- CGEN 2000
- OCCI N/A
- Fundamental
- Price
- CGEN $1.43
- OCCI $5.71
- Analyst Decision
- CGEN
- OCCI
- Analyst Count
- CGEN 0
- OCCI 0
- Target Price
- CGEN N/A
- OCCI N/A
- AVG Volume (30 Days)
- CGEN 217.0K
- OCCI 115.8K
- Earning Date
- CGEN 08-06-2025
- OCCI 12-11-2023
- Dividend Yield
- CGEN N/A
- OCCI 24.32%
- EPS Growth
- CGEN N/A
- OCCI N/A
- EPS
- CGEN N/A
- OCCI N/A
- Revenue
- CGEN $22,144,000.00
- OCCI N/A
- Revenue This Year
- CGEN N/A
- OCCI N/A
- Revenue Next Year
- CGEN $105.77
- OCCI $10.19
- P/E Ratio
- CGEN N/A
- OCCI N/A
- Revenue Growth
- CGEN N/A
- OCCI N/A
- 52 Week Low
- CGEN $1.13
- OCCI $5.47
- 52 Week High
- CGEN $2.66
- OCCI $10.15
- Technical
- Relative Strength Index (RSI)
- CGEN 37.47
- OCCI 41.69
- Support Level
- CGEN $1.43
- OCCI $5.37
- Resistance Level
- CGEN $1.53
- OCCI $6.04
- Average True Range (ATR)
- CGEN 0.06
- OCCI 0.14
- MACD
- CGEN 0.00
- OCCI 0.00
- Stochastic Oscillator
- CGEN 44.44
- OCCI 47.89
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.